ReviewRSC advances2020
Rational design of yolk-shell nanostructures for drug delivery.
Review in RSC advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Engineered Yolk-Shell Nanocarriers for Biphasic Release and Efficient Codelivery of Chemotherapy Drugs in Lung Cancer Cells.ACS omega · 2026Article
- Microfluidic fabrication of rattle shaped biopolymer microcapsules via sequential phase separation in oil droplets.Scientific reports · 2025Article
- Diaminonaphthalene functionalized LUS-1 as a fluorescence probe for simultaneous detection of HgScientific reports · 2024Article
- Recent advances in covalent organic frameworks (COFs) for wound healing and antimicrobial applications.RSC advances · 2023Review
- Research progress of yolk-shell structured nanoparticles and their application in catalysis.RSC advances · 2023Review
- Advanced MXene-Based Micro- and Nanosystems for Targeted Drug Delivery in Cancer Therapy.Micromachines · 2022Review
- Magnetically recoverable catalysts for the preparation of pyridine derivatives: an overview.RSC advances · 2021Review
- New advances on Au-magnetic organic hybrid core-shells in MRI, CT imaging, and drug delivery.RSC advances · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Yolk-shell nanoparticles (YSNPs) are a new class of hollow nanostructures, and their unique properties can be utilized in drug delivery systems. The recent progress in YSNPs-based carriers is highlighted in drug delivery systems. Doxorubicin hydrochloride, ceftriaxone sodium, and methotrexate are three of the most common drugs that are used in this field. According to the reported studies, the materials used most often as yolk-shells are magnetic nanoparticles and polymers. The used methods for synthesizing a diverse array of YSNPs are classified based on their core structures. Various properties of YSNPs include their high drug-loading capacity, and their ability to decrease drug toxicity and satisfactorily and efficiently release drugs.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.